Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

Home

ESTA

E

Establishment Labs Holdings Inc. (ESTA)

NCM – Real vaqt narxi. Valyuta: USD

55.31

-4.60 (-7.68%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

55.31

0.00 (0.00%)

Bozordan keyin: Mar 27, 2026, 6:33 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Carillon Eagle Small Cap Growth Fund Q4 2025 Portfolio Review

Carillon Eagle Small Cap Growth Fund Q4 2025 Portfolio Review

Coherent is expected to continue to benefit from a transition to products that enable faster throughput speeds, while prior constraints on manufacturing capacity appear to be alleviating. BrightSpring Health Services reported another strong quarter with both revenues and EBITDA up significantly, far outpacing its historical growth rate prior to going public in 2024. Varonis Systems, which provides data protection security software, delivered disappointing earnings results and an outlook below expectations.

Establishment Labs Holdings Inc. (ESTA) Reports Q4 Loss, Tops Revenue Estimates

Establishment Labs Holdings Inc. (ESTA) Reports Q4 Loss, Tops Revenue Estimates

Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.98 per share a year ago.

Establishment Labs Holdings Inc. (ESTA) Q4 2025 Earnings Call Transcript

Establishment Labs Holdings Inc. (ESTA) Q4 2025 Earnings Call Transcript

Establishment Labs Holdings Inc. (ESTA) Q4 2025 Earnings Call Transcript

Establishment Labs Announces Leadership Transition to Support Next Phase of Growth

Establishment Labs Announces Leadership Transition to Support Next Phase of Growth

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced a strategic leadership transition of Raj Denhoy, current Chief Financial Officer to Senior Vice President, Global Strategy, and the appointment of Cassandra “Sandra” Harris to Senior Vice President and Chief Financial Officer, effective March 9, 2026. “Over the past.

Establishment Labs Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance

Establishment Labs Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the fourth quarter and full year ended December 31, 2025 and provided 2026 guidance. Fourth Quarter Highlights and Outlook Fourth quarter revenue of $64.6 million, an increase of 45.2% from the year-ago period. 2025 revenue of $211.1 million, a.

Establishment Labs to Present at TD Cowen's 46th Annual Health Care Conference

Establishment Labs to Present at TD Cowen's 46th Annual Health Care Conference

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in TD Cowen's 46th Annual Health Care Conference. Peter Caldini, Chief Executive Officer, and Raj Denhoy, Chief Financial Officer, are scheduled to present in a fireside chat on Monday, March 2, 2026 at 9:10 a.m. ET. A live webcast of the presentat.

Baron Discovery Fund Q4 2025: Winners, Laggards, Buys & Sells

Baron Discovery Fund Q4 2025: Winners, Laggards, Buys & Sells

In the fourth quarter of 2025, the Baron Discovery Fund returned 0.19% (Institutional Shares), trailing the Russell 2000 Growth Index by 1.03%. In these periods, low quality (high debt and poor profitability) and short-term price momentum-oriented stocks outperformed. Exact Sciences Corporation received a buyout offer in the fourth quarter by Abbott Laboratories (ABT) for a price of $105 in cash.

Videolar

No Data

There is no data to display

Press-relizlar

Establishment Labs Announces Leadership Transition to Support Next Phase of Growth

Establishment Labs Announces Leadership Transition to Support Next Phase of Growth

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced a strategic leadership transition of Raj Denhoy, current Chief Financial Officer to Senior Vice President, Global Strategy, and the appointment of Cassandra “Sandra” Harris to Senior Vice President and Chief Financial Officer, effective March 9, 2026. “Over the past.

Establishment Labs Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance

Establishment Labs Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the fourth quarter and full year ended December 31, 2025 and provided 2026 guidance. Fourth Quarter Highlights and Outlook Fourth quarter revenue of $64.6 million, an increase of 45.2% from the year-ago period. 2025 revenue of $211.1 million, a.

Establishment Labs Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2025

Establishment Labs Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2025

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced preliminary unaudited financial results for the three months and fiscal year ended December 31, 2025. Establishment Labs' preliminary unaudited revenue for the fourth quarter of 2025 is expected to be in the range of $64.0 million to $65.0 million, including $17.0 m.

Establishment Labs Submits to FDA for Approval of Motiva Implants in Breast Reconstruction

Establishment Labs Submits to FDA for Approval of Motiva Implants in Breast Reconstruction

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced that it has submitted Motiva® implants for approval in primary and revision breast reconstruction to the U.S. Food and Drug Administration (FDA). The products were previously approved by the FDA for use in breast augmentation on September 27, 2024. “Expanding our FD.